Compare Stocks → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:CNATOTCMKTS:ICOTFNASDAQ:IMRNNASDAQ:ONCY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$4.93+3.8%$5.40$1.01▼$7.42$80.62M2.2264,570 shs102,247 shsCNATConatus Pharmaceuticals$0.35$1.00$0.23▼$1.07$11.61M1.841.28 million shs6,956 shsICOTFiCo Therapeutics$0.34-5.5%$0.37$0.80▼$1.82$3.09M2.034,760 shs1,200 shsIMRNImmuron$2.49+1.2%$5.04$1.92▼$28.99$14.19M1.4323,679 shs1,273 shsONCYOncolytics Biotech$1.06$1.07$0.88▼$3.39$79.95M1.93369,956 shs61,862 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+3.79%+16.00%-14.56%+1.86%+230.89%CNATConatus Pharmaceuticals+0.03%-29.98%-10.23%+3.79%-63.16%ICOTFiCo Therapeutics-5.31%-7.92%-5.36%-13.49%-33.84%IMRNImmuron-1.58%+3.32%-4.60%+34.59%+16.90%ONCYOncolytics Biotech0.00%+1.92%+2.91%-15.20%-6.19%At first glance, this chart looks like nonsense… (Ad)We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.8788 of 5 stars3.53.00.00.02.41.70.0CNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech0.8071 of 5 stars3.53.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00285.40% UpsideCNATConatus PharmaceuticalsN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$4.00277.36% UpsideCurrent Analyst RatingsLatest CNAT, ALRN, IMRN, ICOTF, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACNATConatus Pharmaceuticals$21.72M0.53N/AN/A$0.53 per share0.66ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AIMRNImmuron$1.22M11.63N/AN/A$2.32 per share1.07ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)CNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/AIMRNImmuron-$2.55MN/A0.00∞N/AN/AN/AN/AN/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)Latest CNAT, ALRN, IMRN, ICOTF, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AIMRNImmuronN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17CNATConatus PharmaceuticalsN/A16.2816.28ICOTFiCo TherapeuticsN/A0.720.72IMRNImmuronN/A8.527.79ONCYOncolytics BiotechN/A9.019.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%CNATConatus Pharmaceuticals15.20%ICOTFiCo TherapeuticsN/AIMRNImmuron0.12%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%CNATConatus Pharmaceuticals11.30%ICOTFiCo TherapeuticsN/AIMRNImmuron7.01%ONCYOncolytics Biotech0.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableIMRNImmuronN/A5.70 million5.30 millionNot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableCNAT, ALRN, IMRN, ICOTF, and ONCY HeadlinesSourceHeadlineClosing Bell: Oncolytics Bio up on Friday (ONC)theglobeandmail.com - April 21 at 5:51 PMBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Casestheglobeandmail.com - April 13 at 12:42 AMUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fightfinanznachrichten.de - April 11 at 2:15 PMOncolytics seeking FDA meeting to discuss registration-enabling studymsn.com - April 11 at 2:15 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAprnewswire.com - April 11 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond Jamesmarketbeat.com - April 4 at 2:58 PMUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergencyfinanznachrichten.de - March 14 at 9:24 AMBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trialsmarkets.businessinsider.com - March 11 at 7:59 AMOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 10 at 10:18 AMBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trialsmarkets.businessinsider.com - March 8 at 8:46 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsfinanznachrichten.de - March 8 at 10:45 AMOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsprnewswire.com - March 7 at 4:01 PMOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANprnewswire.com - March 5 at 7:00 AMOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conferenceprnewswire.com - February 28 at 7:00 AMHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situationfinance.yahoo.com - February 15 at 3:44 PMOncolytics Biotech Incbaystreet.ca - February 15 at 10:44 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsnewsfilecorp.com - February 15 at 8:00 AMOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 1:27 PMOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinance.yahoo.com - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortprnewswire.com - February 14 at 7:00 AMOutlook stock rallies on private placement, FDA study agreementmsn.com - January 23 at 11:32 AMOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinanznachrichten.de - January 9 at 7:50 AMOncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinance.yahoo.com - January 9 at 7:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Conatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.iCo TherapeuticsOTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.ImmuronNASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.